Understanding the Current State of M&A: Q&A with Cheryl Reicin
Member Cheryl Reicin participated in a Q&A with Pharmaceutical Executive focused how mergers and acquisitions are trending in the pharma industry.
Cheryl discusses the policy shifts and regulatory changes that can be expected in the next year. She says, “The current administration and the Harris team are looking to introduce price controls for certain drugs. If implemented, this is likely to have a chilling effect on the development and investment in new therapeutics. The high cost of drugs is intended to compensate for the high cost of bringing an innovative drug to market, which includes the high costs of the many failures of drugs that do not reach the market. If the price of a drug is controlled, the upside to pharma is limited, and therefore the investment thesis for the development of new drugs can shift dramatically.”
Source